VRCANasdaqPharmaceutical PreparationsFiscal year ends December 31
Verrica Pharmaceuticals Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.44−0.16 (-4.31%)
Close on Oct 19, 2026
- Market cap
- $73.29M
- P/E (TTM)
- –
- Dividend yield
- –
Verrica Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Verrica Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $59.10M | $166.30M |
| Enterprise Value | $47.90M | $88.19M |
| PS Ratio | 1.95 | 3.65 |
| PB Ratio | 13.72 | 2.03 |
| P/TBV Ratio | 13.72 | 2.29 |
Enterprise value
| Measure | Verrica Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 1.58 | 2.51 |
Income (trailing twelve months)
| Measure | Verrica Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $30.32M | $58.34M |
| Operating Income | -$28.38M | -$21.40M |
| Net Income | -$31.18M | -$22.46M |
| EBITDA | -$28.38M | -$16.91M |
| EPS (Diluted) | -$1.67 | -$0.83 |
Margins
| Measure | Verrica Pharmaceuticals | Industry median |
|---|---|---|
| Operating Margin | -93.6% | -44.0% |
| Profit Margin | -102.8% | -40.2% |
| EBITDA Margin | -93.6% | -30.2% |
Returns
| Measure | Verrica Pharmaceuticals | Industry median |
|---|---|---|
| Return on Assets (ROA) | -83.0% | -40.9% |
| Return on Capital Employed (ROCE) | -209.0% | -38.1% |
Growth
| Measure | Verrica Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 106.2% | 5.96% |
| Revenue Growth (3Y CAGR) | 57.9% | 2.25% |
Balance sheet
| Measure | Verrica Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $11.20M | $61.43M |
| Net Cash (Debt) | $11.20M | $15.35M |
| Net Cash Per Share | $0.65 | $0.66 |
| Equity (Book Value) | $4.31M | $49.09M |
| Book Value Per Share | $0.25 | $1.37 |
| Tangible Book Value | $4.31M | $23.52M |
| Working Capital | $10.20M | $76.81M |
Financial position
| Measure | Verrica Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 1.45 | 3.34 |
| Quick Ratio | 0.99 | 2.44 |
| Interest Coverage | -7.60 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Verrica Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$13.35M | -$12.35M |
Efficiency
| Measure | Verrica Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.81 | 0.39 |
| Revenue Per Employee | $398.96K | $404.87K |
| Profits Per Employee | -$410.30K | -$703.34K |
| Employee Count | 76 | 74 |
Dividends and yields
| Measure | Verrica Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -52.8% | -23.3% |
Shares
| Measure | Verrica Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 17,178,800 | 58,127,000 |
| Shares Change (YoY) | 117.9% | 10.9% |
| Shares Change (QoQ) | 0.00% | 0.54% |
| Shares Held by Institutions | 27.1% | 59.4% |
Scores
| Measure | Verrica Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | -13.82 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Verrica Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.